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Because the resistance of pathogenic bacteria towards avail-
able antibiotics is rapidly becoming a major worldwide prob-
lem; the design of new class of chemical moieties to deal
with resistance bacteria has become one of the important areas
of antibacterial research today. In addition, fungal infections
continue to increase rapidly because of the increased number
of immuno compromised patients. As known, not only bio-
chemical similarity of the human cell and fungi forms a hand-
icap for selective activity, but also the easily gained resistance
is the main problem noticed in developing safe and efﬁcient
antifungals. On the other hand,Mycobacterium tuberculosis re-mains a leading infectious and most dangerous cause of death
in the world today. So, it is necessary to design a new kind of
antimicrobial and anti tubercular agents.
Thiazoles are familiar class of heterocyclic moieties possess-
ing awide variety of biological activities and their utility asmed-
icine is very much-established (Liaras et al., 2011). Several
physiological activities of thiazole derivatives have proved the
efﬁciency in combating various diseases and noticed to have
good antimicrobial activities (Vicini et al., 2006). Among the
important heterocycles, thiadiazoles are one of the privileged
structural fragments in medicinal chemistry due to various bio-
logical activities, such as anti cancer (Matysiak et al., 2007), anti
tubercular (Solak et al., 2006; Foroumadi et al., 2002), antibac-
terial (Thomasco et al., 2003; Kadi et al., 2007; Faroumadi
et al., 2005a,b), antidepressants (Varvaresou et al., 1998; Yusuf
et al.,2008), leishmanicidal (Faroumadi et al., 2005a,b) and
anti-inﬂammatory agents (Schenone et al., 2006). On the other
hand pyrazoles are an important class of heterocycles and ear-
lier workers have been synthesized and reported various pyra-
zole derivatives as antifungal (Prakash et al., 2008), antiviral
(Genin et al., 2000), anti proliferative (Schenone et al., 2004),
34 N. Seelam, S.P. Shrivastavaantimicrobial (Tanitame et al., 2005; Tandon et al., 2005; Kane
et al., 2003; Kucukgezel et al., 2000), anti parasitic (Kuettel
et al., 2007) and anti neoplastic agents (Farag et al. 2008; Diana
et al., 2007).
In view of the above mentioned facts it was contemplated
to design and synthesize some 3,5-diphenyl-6-(5-p-tolyl-1,3,
4thiadiazol-2-yl)-3,3a,5,6-tetrahydro-2H pyrazolo3,4-dthiazole
derivatives and evaluate their antimicrobial and anti-tubercu-
lar activities.
2. Experimental
2.1. Chemistry
All melting points were measured on open capillary method.
IR spectra were recorded for KBr disc on a Schimadzu-8400
FTIR spectrophotometer. 1H NMR, 13C NMR spectra were
measured on a Bruker Avance II 400 spectrometer, operating
at 400, 100.6 MHz, respectively. Chemical shifts (d) are re-
ported in parts per million and TMS as an internal standard.
Molecular weights were determined with TOF MS ES Mass
spectra. Reactions were monitored by thin layer chromatogra-
phy (TLC) on silica gel, plates were visualized with ultraviolet
light or iodine. Column chromatography was performed on sil-
ica gel 60 (0.043–0.06 mm) Merck.
2.1.1. General procedure for the synthesis of p-methyl benzoyl
thiosemicarbazide: 1
A mixture of ethyl-p-methyl benzoate (0.01 mol) and thiosem-
icarbazide (0.01 mol) in methanol (25 ml) was reﬂuxed for
10 h. The solvent was removed under reduced pressure and
the viscous mass poured over ice water, ﬁltered and recrystal-
lized from methanol–water to afford compound 1. m.p. 128–
30 C, yield 75%, IR (KBr) m in cm1: 2942.16 (CH3), 3060
(C–H in aromatic), 3175 (N–H), 1661.53 (C‚O), 1071.6
(C‚S), 1H NMR (400 MHz, CDCl3) & in ppm: 7.60–7.45
(m, 4H, Ar–H), 8.15 (m, 4H, NHNHCSNH2 exchangeable
with D2O), 2.91 (s, 3H, CH3).
2.1.2. General procedure for the synthesis of 5-p-Tolyl-
1,3,4thiadiazol-2-yl amine 2
A mixture of compound 1 (0.05 mol) and conc. H2SO4 (20 ml)
was kept overnight at room temperature, then poured into
cold water, neutralized with liquid ammonia and ﬁltered.
The product thus obtained was recrystallized from ethanol–
water. m.p. 135 C, yield 61%; IR (KBr) m in cm1 3350
(NH2); 3058 (C–H in aromatic), 2968.63 (CH3); 1598
(C‚N), 1221 (C–N), 1045 (N–N), 732.27 (C–S–C); 1H
NMR (400 MHz, CDCl3) d in ppm; 7.62–7.35 (m, 4H, Ar–
H), 6.35 (bs, 2H, NH2 exchangeable with D2O), 3.01 (s, 3H,
CH3).
2.1.3. General procedure for the synthesis of Benzylidene-(5-p-
tolyl-1,3,4thiadiazol-2-yl)-amine 3
A mixture of 2 (0.01 mol) and benzaldehyde (0.01 mol) was re-
ﬂuxed in ethanol for 5 h with a few drops of glacial acetic acid.
The solid separated on cooling was ﬁltered, dried and recrys-
tallized from benzene as needle shaped crystals were obtained.
Yield 73.2%, m.p.162–64 C; IR (KBr) m in cm1: 3032.2
(Ar–H), 2946.76 (C–H in CH3), 1040.6 (N–N), 1608.61
(C‚N cyclic), 1221 (C–N), 683.7 (C–S); 1H NMR(400 MHz, DMSO-d6) d: 6.79–7.21 (m, 9H, Ar–H), 7.9 (s,
1H, N‚CH), 2.96 (s, 3H,CH3).
2.1.4. General procedure for the synthesis of 2-Phenyl-3-(5-p-
tolyl-1,3,4thiadiazol-2-yl)-thiazolidin-4-one.4
A mixture of compound 3 (0.01 mol) and mercapto acetic acid
(0.01 mol) in 1,4-dioxane (30 ml) containing a pinch of ZnCl2
was reﬂuxed for 8 h. The hot solution was ﬁltered and cooled
in an ice bath. The solid obtained was ﬁltered, washed with
10% NaHCO3 solution and was recrystallized from alcohol.
Yield 70.9%, m.p. 181–184 C; IR (KBr) m in cm1: 2946.73
(C–H in CH3), 2918.69 (C–H in CH2), 1665 (C‚O), 1608.61
(C‚N), 1045.1 (N–N), 691.6 (C–S), 1H NMR (400 MHz,
DMSO-d6) d: 6.91–7.8 (m, 9H, Ar–H), 5.13 (s, 1H, N–CH–
Ar), 4.25 (s, 2H, SCH2C‚O), 2.91 (s, 3H, CH3).
2.1.5. General procedure for the synthesis of 5-(4-Chloro-
benzylidene)-2-phenyl-3-(5-p-tolyl-1,3,4thiadiazol-2-yl)-
thiazolidin-4-one.5a
A mixture of compound 4 (0.01 mol), 4-chloro benzaldehyde
(0.01 mol) and anhydrous sodium acetate (0.005 mol) in anhy-
drous glacial acetic acid (50 ml), was reﬂuxed for 3 h. The reac-
tion mixture was concentrated and then poured into ice cold
water, the solid thus separated was ﬁltered, washed with water
and recrystallized from glacial acetic acid to afford pure brown
color solid. Yield: 59.5%; m.p. 206–08 C; IR (KBr) m in cm1;
3032.2 (Ar–H), 2946.73 (CH in CH3), 1608.61 (C‚N), 1099.07
(C–Cl), 1042.61 (N–N), 1665 (C‚O), 1H NMR (400 MHz,
DMSO-d6) d: 7.22–7.9 (m, 11H, Ar–H), 7.13 (d,
J = 9.1 MHz, 2H, Ar–H near Cl), 6.89(s, 1H, ‚CH), 5.13
(s, 1H, N–CH–Ar), 2.93 (s, 3H, CH3);
13C NMR: d: 157.1
(C‚O in ring), 135.5, 131.9, 130.7, 129.5, 128.0, 127.7, 118.9
(Ar–H), 154.2, 152.1(C in thiadiazole ring), 50.7 (‚CH),
69.9 (N–CH–Ar), 22.5 (CH3). MS: m/z 477.90 (M+2, 32.5),
476.81 (M+1, 26.8), 475.95 (M+, 28.9), 91 (100).
Similarly other compounds 5b–g were also synthesized and
their characteristic analytical data are given below.
2.1.5.1. 5-(4-Nitro-benzylidene)-2-phenyl-3-(5-p-tolyl-1,3,4thia-
diazol-2-yl)-thiazolidin-4-one.5b. Yield: 58%; m.p. 197–99 C;
IR (KBr) m in cm1; 3032.2 (Ar–H), 2948.72 (CH in CH3),
1608.29 (C‚N), 1665.49 (C‚O), 1541.18 (N–O), 1042.61
(N–N), 1H NMR (400 MHz, DMSO-d6) d: 7.86 (d,
J = 8.3 MHz, 2H, Ar–H near NO2), 7.1–7.7 (m, 9H, Ar–H),
6.99 (d, J = 9.1 MHz, 2H, Ar–H), 6.86(s, 1H, ‚CH), 5.13
(s, 1H, N–CH–Ar), 2.76 (s, 3H, CH3);
13C NMR: d: 162.3
(C‚O in ring), 148.93, 138.7, 133.1, 128.7, 123.1, 119.6 (Aro-
matics), 155.7, 153.9 (C in thiadiazole ring), 69.9 (N–CH–Ar),
51.3 (‚CH), 22.9 (CH3). MS: m/z 487.34 (M+1, 30), 486.29
(M+, 29.7), 91 (100).
2.1.5.2. 5-(4-Dimethylamino-benzylidene)-2-phenyl-3-(5-p-
tolyl-1,3,4thiadiazol-2-yl)-thiazolidin-4-one.5c. Yield 61%,
m.p. 208–10 C, IR (KBr) m in cm1; 3032.2 (CH in Ar),
2952(CH in CH3), 1611.23 (C‚N), 1683.09 (C‚O), 1038.61
(N–N), 1225.6 (C–N); 1H NMR (400 MHz, DMSO-d6) d:
6.61 (d, J = 9.1 MHz, 2H, Ar–H near NMe2), 6.49 (d,
J = 9.1 MHz, 2H, Ar–H), 6.79(s, 1H, ‚CH), 5.07 (s, 1H,
N–CH–Ar), 2.93(s, 6H, CH3), 2.68 (s, 3H, CH3), 6.8–7.3 (m,
9H, Ar–H); 13C NMR: d: 159.7 (C‚O), 151.1, 133.7, 135.6,
128.6, 117.01, 113.6 (Aromatics), 154.2, 153.01(C in thiadia-
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485.58 (M+1, 31.3), 484.49 (M+, 29.7), 91 (100).
2.1.5.3. 5-(3-Nitro-benzylidene)-2-phenyl-3-(5-p-tolyl-1,3,4thia-
diazol-2-yl)-thiazolidin-4-one.5d. Yield 59.6%, m.p. 201–03 C;
IR (KBr) m in cm1 ; 3032.21 (CH in Ar), 2948.72 (CH in
CH3), 1683.91 (C‚O), 1552.29 (C‚N), 1537.28 (N–O),
1040.23 (N–N); 1H NMR (400 MHz, DMSO-d6) d: 7.91 (d,
J = 8.5 MHz, 2H, Ar–H near NO2), 6.85 (d, J = 9.1 MHz,
2H, Ar–H), 6.9(s, 1H, ‚CH), 6.96–7.58 (m, 9H, Ar–H), 5.27
(s, 1H, N–CH–Ar), 2.91 (s, 3H, CH3).
2.1.5.4. 5-(4-Methoxy-benzylidene)-2-phenyl-3-(5-p-tolyl-
1,3,4thiadiazol-2-yl)-thiazolidin-4-one.5e. Yield 61%,
m.p.198–200 C; IR (KBr) m in cm1; 3049.13 (CH in Ar–H),
2943.65 (CH in CH3), 1552.29 (C‚N), 1226.77 (C–N),
1248.69 (C–O–C), 1040.23 (N–N), 1683.91 (C‚O); 1H NMR
(400 MHz, DMSO-d6) d: 7.0–7.41 (m, 11H, Ar–H), 6.8 (d,
J = 9.0 MHz, 2H, Ar–H near OCH3), 6.91 (s, 1H, ‚CH),
5.8 (s, 1H, N–CH–Ar), 3.58 (s, 3H, OCH3), 2.92 (s, 3H, CH3).
2.1.5.5. 2-Phenyl-3-(5-p-tolyl-1,3,4thiadiazol-2-yl)-5-(3,4,5-tri-
methoxy-benzylidene)-thiazolidin-4-one.5f. Yield 62%, m.p.
214–17 C; IR (KBr) m in cm1: 3049.13 (CH in Ar–H),
2943.65 (CH in CH3), 1552.29 (C‚N), 1251.84 (C–O–C),
1040.23 (N–N), 1683.91 (C‚O). 1H NMR (400 MHz,
DMSO-d6) d: 7.86 (d, J = 8.3 MHz, 2H, Ar–H near OCH3),
6.92 (d, J = 9.1 MHz, 2H, Ar–H), 7.1–7.63 (m, 7H, Ar–H),
6.81(s, 1H, ‚CH), 5.68 (s, 1H, N–CH–Ar), 3.81 (s, 6H,
OCH3), 3.65 (s, 3H, OCH3), 2.93 (s, 1H, CH3).
2.1.5.6. 5-(4-Bromo-benzylidene)-2-phenyl-3-(5-p-tolyl-
1,3,4thiadiazol-2-yl)-thiazolidin-4-one.5g. yield 60.3%, m.p.
209–12 C; IR (KBr) m in cm1; 3049.13 (CH in Ar–H),
2943.65 (CH in CH3), 1683.91 (C–O), 1552.29 (C‚N),
1040.23 (N–N); 1H NMR (400 MHz, DMSO-d6) d: 7.05–
7.38(m, 13H, Ar–H), 6.76(s, 1H, ‚CH), 5.95(s, 1H, N–CH–
S), 2.31(s, 3H, CH3);
13C NMR: d: 159.7 (C‚O), 132.7,
131.2, 128.9, 124.8 (Ar–H), 155.1, 153.9 (C in thiadiazole ring),
51.8 (‚CH), 69.8 (N–CH–Ar), 27.1 (CH3); MS: m/z 522.13
(M+2, 31.2), 521.19 (M+1, 27.8), 520.15 (M+, 28.6), 91
(100).
2.1.6. General procedure for the synthesis of 3-(4-Chloro-
phenyl)-5-phenyl-6-(5-p-tolyl-1,3,4thiadiazol-2-yl)-3,3a,5,6-
tetrahydro-2H-pyrazolo-3,4-dthiazole 6a
A mixture of compound 5a (0.01 mol), hydrazine hydrate
(0.01 mol) and anhydrous sodium acetate (0.005 mol) in anhy-
drous glacial acetic acid (50 ml), was reﬂuxed for 8 h. The reac-
tion mixture was concentrated and then poured into ice cold
water. The solid thus separated was ﬁltered, washed with water
and recrystallized from ethanol to afford pure compound 6a;
Yield 51.2%, m.p. 236–38 C; IR (KBr) m in cm1; 3265.19
(N–H), 3032.2 (CH in Ar–H), 2957.21 (CH in CH3), 1558.54
(C‚N), 1097.16 (C–Cl), 1040.23 (N–N), 1H NMR
(400 MHz, DMSO-d6) d: 8.1 (s, 1H, N–H), 7.31–7.86 (m,
11H, Ar–H), 7.27 (d, J = 9.1 MHz, 2H, Ar–H near Cl), 5.08
(s, 1H, N–CH–Ar), 4.69 (d, J = 2.3 MHz, 1H, CH–N), 4.11
(d, J = 2.3 MHz, 1H, CH–S), 2.68 (s, 3H, CH3).
13C NMR:
d: 154.7 (C‚N in fused ring), 154.2, 151.6 (C in thiadiazole
ring), 139.4, 135.9, 131.2, 130.8, 127.7, 118.9 (Ar–H), 66.1
(N–CH-S), 52.9 (CH-N), 53.7(CH), 25.6(CH3). MS: m/z491.56 (M+2, 35.1), 490.43 (M+1, 27.8), 489.50(M+, 29.1),
91(100).
Other compounds 6b–g were also synthesized in the similar
manner using compounds 5b–g. Characterization data are gi-
ven below.
2.1.6.1. 3-(4-Nitro-phenyl)-5-phenyl-6-(5-p-tolyl-1,3,4thia-
diazol-2-yl)-3,3a,5,6-tetrahydro-2H-pyrazolo-3,4-dthiazole 6b.
Yield 52%, m.p. 244–46 C; IR (KBr) m in cm1; 3265.19
(N–H in ring), 3032.2 (CH in Ar), 2957.21 (CH in CH3),
1558.54 (C‚N), 1541.18 (N–O), 1040.23 (N–N), 1H NMR
(400 MHz, DMSO-d6) d: 8.1 (s, 1H, N–H), 7.68 (d,
J = 8.6 MHz, 2H, Ar–H near NO2), 6.9–7.46 (m, 11H, Ar–
H), 5.19 (s, 1H, N–CH–Ar), 4.69 (d, J = 2.2 MHz, 1H, CH–
N), 4.38 (d, J = 2.2 MHz, 1H, CH–S), 2.78 (s, 3H, CH3);
13C NMR: d: 158.3 (C‚N in fused ring), 155.3, 153.7 (C in
thiadiazole ring), 147.12, 138.7, 133.5, 129.1, 123.7 (Aromat-
ics), 69.9 (N–CH–Ar), 52.26(CH), 51.8(CH–S), 25.6 (CH3).
MS: m/z 501.41 (M+1, 28.1), 500.36 (M+, 31), 91 (100).
2.1.6.2. 3-(4-Dimethylamino-phenyl)-5-phenyl-6-(5-p-tolyl-
1,3,4thiadiazol-2-yl)-3,3a,5,6-tetrahydro-2H-pyrazolo-3,4-
dthiazole 6c. Yield 50.8%, m.p. 256–58 C; IR (KBr) m in cm
1; 3246.21 (N–H), 3032.2 (CH in Ar), 2968.55, 2926.1 (CH
in CH3), 1558.54 (C‚N), 1266.77 (C–N), 1091.75 (N–N),
1H
NMR (400 MHz, DMSO-d6) d: 8.08 (s, 1H, N–H), 6.95–7.6
(m, 11H, Ar–H), 6.87 (d, J = 9.1 MHz, 2H, Ar–H near
NMe2), 5.47 (s, 1H, N–CH–Ar), 4.53 (d, J = 2.3 MHz, 1H,
CH–N), 4.11 (d, J = 2.3 MHz, 1H, CH–S) 2.95 (s, 6H,
CH3), 2.73 (s, 3H, CH3);
13C NMR: d: 156.7 (C‚N in fused
ring), 148.93, 135.6, 132.2, 128.6, 116.2, 114.1 (Aromatics),
155.1, 153.7 (C in thiadiazole ring), 68.1 (N–CH–Ar), 54.1
(CH), 52.9 (CH–N), 42.8 (C in N–CH3), 29.8 (CH3). MS: m/
z 499.53 (M+1, 30.8), 498.51 (M+, 27.8), 91 (100).
2.1.6.3. 3-(3-Nitro-phenyl)-5-phenyl-6- (5-p-tolyl-1,3,4thia-
diazol-2-yl)-3,3a,5,6-tetrahydro-2H-pyrazolo-3,4-dthiazole 6d.
6d: Yield 49.7%, m.p. 245–48 C; IR (KBr) m in cm1;
3265.19 (N–H), 3032.2 (CH in Ar), 2957.21 (CH in CH3),
1543.7 (N–O), 1558.54 (C‚N), 1040.23 (N–N), 1H NMR
(400 MHz, DMSO-d6) d: 8.01 (s, 1H, N–H), 7.81 (d,
J = 8.3 MHz, 2H, Ar–H near NO2), 6.95–7.68 (m, 11H, Ar–
H), 5.36 (s, 1H, N–CH–Ar), 4.87 (d, J = 2.2 MHz, 1H, CH–
N), 4.49 (d, J = 2.2 MHz, 1H, CH–S), 2.78 (s, 3H, CH3);
13C NMR: d: 158.1 (C‚N in fused ring), 146.78, 138.7,
134.3, 129.6, 123.0 (aromatics), 154.5, 152.8 (C in thiadiazole
ring), 68.9 (N–CH–Ar), 52.3 (CH), 51.6 (CH-N), 28.5 (CH3).
MS: m/z 501.41 (M+1, 28.5), 500.38 (M+, 30.3), 91 (100).
2.1.6.4. 3-(4-Methoxy-phenyl)-5-phenyl-6-(5-p-tolyl-1,3,4thia-
diazol-2-yl)-3,3a,5,6-tetrahydro-2H-pyrazolo-3,4-dthiazole 6e.
Yield 51%, m.p. 249–51 C; IR (KBr) m in cm1; 3265.19
(N–H), 3032.2 (CH in Ar), 2957.21 (CH in CH3), 1248.7
(C–O–C), 1040.23 (N–N), 1H NMR (400 MHz, DMSO-d6)
d: 8.08 (s, 1H, N–H), 6.9–7.71 (m, 13H, Ar–H), 5.41 (s, 1H,
N–CH–Ar), 4.91 (d, J = 2.2 MHz, 1H, CH–N), 4.49 (d,
J = 2.2 MHz, 1H, CH–S), 3.81 (s, 3H, OCH3), 2.78 (s, 3H,
CH3);
13C NMR: d: 158.1 (C‚N in fused ring), 160.3, 136.1,
129.8, 127.6, 121.5, 115.9 (aromatics), 155.1, 153.6 (C in thia-
diazole ring), 68.9 (N–CH–Ar), 55.2 (OCH3), 53.2 (CH), 52.01
(CH–N), 28.6 (CH3). MS: m/z 486.39 (M+1, 30.1), 485.44
(M+, 28.9), 91 (100).
Table 2 Anti tubercular activity of selected compounds of
series 6a–g (MIC lg/ml).
No. Compounds MIC (lg/ml) H37Rv
1 6a 6.25
2 6b 3.125
3 6c 25
4 6d >6.25
5 6e >25
6 6f 25
7 6g 3.125
8 Isoniazid 0.2
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methoxy-phenyl)3,3a,5,6-tetrahydro-2H-pyrazolo3,4-dthiazole
6f. Yield 52.5%, m.p. 238–40 C; IR (KBr) m in cm1; 3265.19
(N–H), 3032.2 (CH in Ar), 2957.21 (CH in CH3), 1251.84 (C–
O–C), 1040.23 (N–N), 1H NMR (400 MHz, DMSO-d6) d: 8.05
(s, 1H, N–H), 7.01–7.89 (m, 11H, Ar–H), 5.7 (s, 1H, N–CH–
Ar), 4.72 (d, J = 2.2 MHz, 1H, CH–N), 4.32 (d,
J = 2.2 MHz, 1H, CH–S), 3.95 (s, 6H, OCH3), 3.68 (s, 3H,
OCH3), 2.31 (s, 3H, CH3);
13C NMR: d: 158.1 (C‚N in fused
ring), 156.75, 136.1, 128.4, 114.21 (aromatics), 154.2, 152.9 (C
in thiadiazole ring), 67.3 (N–CH–Ar), 56.81 (OCH3), 53.2
(CH), 50.9 (CH–N), 23.9 (CH3). MS: m/z 546.21 (M+1,
26.8), 545.30 (M+, 27.1), 91 (100).
2.1.6.6. 3-(4-Bromo-phenyl)-5-phenyl-6-(5-p-tolyl-1,3,4thia-
diazol-2-yl)-3,3a,5,6-tetrahydro-2H-pyrazolo-3,4-dthiazole 6g.
Yield 51.8%, m.p. 244–46 C, IR (KBr) m in cm1; 3265.19
(N–H), 3032.2 (CH in Ar), 2957.21 (CH in CH3), 1040.23
(N–N), 1H NMR (400 MHz, DMSO-d6) d: 8.10 (s, 1H,
N–H), 6.87–7.68 (m, 13H, Ar–H), 5.68 (s, 1H, N–CH–Ar),
4.72 (d, J = 2.2 MHz, 1H, CH–N), 4.45(d, J = 2.2 MHz,
1H, CH–S), 2.59 (s, 3H, CH3);
13C NMR: d: 158.3 (C‚N in
fused ring), 133.4, 131.6, 127.1, 124.3, 119.2 (aromatics),
155.3, 152.9 (C in thiadiazole ring), 67.3 (N–CH–Ar), 52.8
(CH), 52.01 (CH–N), 25.7 (CH3). MS: m/z 535.9 (M+2,
31.9), 534.97 (M+1, 28.4), 533.88 (28.6), 91 (100).
2.2. Pharmacology
2.2.1. Antimicrobial activity
The newly prepared compounds 6a–g were screened for their
antimicrobial activity. This activity was determined by disc dif-
fusion method. In this work Bacillus subtilis, Bacillus thuringi-
ensis, Escherichia coli and Pseudomonas aeruginosa bacterial
strains were used, and Candida albicans, Botrytis fabae and Fu-
sarium oxysporum fungal strains were used. The compounds
were dissolved in DMSO at a concentration of 1 mgml1.
The antibacterial activity of each compound was compared
with the standard drug Streptomycin and antifungal activity
with Treﬂucan.
2.2.2. Anti tuberculosis activity
All the synthesized compounds of series (6a–g) were evaluated
for their anti tubercular activity. Drug susceptibility and deter-Table 1 Antimicrobial activity of compounds 6a–g (MIC lg/ml).
Comp’ No. Bacteriab
B. subtilis B. thuringiensis E. coli
6a 3.125 6.25 12.5
6b 3.125 3.125 6.25
6c 25 25 50
6d 6.25 6.25 12.5
6e 12.5 25 25
6f 12.5 12.5 12.5
6g 3.125 3.125 3.125
Streptomycin 3.125 6.25 6.25
Treﬂu can NAa NAa NAa
a Not Active.
b B. subtilis (MTCC No: 1133), B. thuringiensis (MTCC No: 4714), E.
c C. albicans (MTCC No: 183), B. fabae (ATCC No: 14862) and F. oxmination of MIC of the test compounds against M. tuberculo-
sis H37Rv were performed by agar micro dilution method,
where two fold dilutions of each test compound were added
into 7H10 agars supplemented with OADC and organism. A
culture of used microorganismM. tuberculosis H37Rv growing
on L–J medium was harvested in 0.85% saline with 0.05%
Tween-80. A suspension of compounds was prepared in
DMSO. This suspension was added to (in tubes) 7H10 middle
brook’s medium (containing 1.7 ml medium and 0.2 ml OADC
supplement) at different concentrations of compound keeping
the volume constant, that is, 0.1 ml medium was allowed to
cool keeping the tubes in slanting position. These tubes were
then incubated at 37 C for 24 h followed by streaking of M.
tuberculosis H37Rv (5 · 104 bacilli per tube). These tubes were
then incubated at 37 C. Growth of bacilli was seen after
30 days of incubation. The concentration at which complete
inhibition of colonies occurred was taken as active concentra-
tion of test compound. Isoniazid was used as standard drug.
The MIC levels of some active compounds (6a–g) against these
organisms were given in Table 2.
3. Results and discussion
3.1. Chemistry
The key intermediate, 4 required for the synthesis of title com-
pounds was prepared according to the procedure outlined in
Scheme 1. Condensation of ethyl p-methyl benzoate with thio-
semicarbazide yielded the compound 1. This compound was
dehydrated with conc. H2SO4 to give compound (5-p-Tolyl-Fungic
P. aeruginosa C. albicans B. fabae F. oxysporam
6.25 3.125 12.5 6.25
12.5 12.5 25 25
25 12.5 12.5 25
12.5 25 50 25
50 3.125 3.125 6.25
50 3.125 3.125 3.125
3.125 25 12.5 25
6.25 NAa NAa NAa
NAa 3.125 3.125 3.125
coli (MTCC No: 443), and P.aeruginosa (MTCC No: 2297).
ysporam (MTCC No: 7392).
Scheme 1 Synthesis of compounds 6a–g. Reaction conditions: (a) Thiosemicarbazide, CH3OH, (b) Conc. H2SO4, (c) Benzaldehyde,
glacial AcOH, C2H5OH. (d) SHCH2COOH, anhydrous ZnCl2, (e) Aromatic aldehydes, Anhydrous CH3COONa, (f) NH2NH2.H2O,
anhydrous. CH3COONa, glacial AcOH.
Synthesis and in vitro study of [1,3,4]thiadiazol-2yl-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d]thiazoles 371,3,4thiadiazol-2-yl amine) 2. Compound 2 was further reacted
with benzaldehyde to give (Benzylidene-(5-p-tolyl-1,3,4thia-
diazol-2-yl)-amine) 3. This was then reacted with mercapto ace-
tic acid in the presence of anhydrous ZnCl2 under conventional
heating conditions to give compound 4 (Scheme 1). Compound
4 was then reacted with various aromatic aldehydes in the pres-
ence of anhydrous NaOAc in glacial AcOH at reﬂux tempera-
ture to give chalcone derivatives of thiazolidinones 5a–g.
Compounds 5a–g on cyclo condensation with hydrazine hy-
drate in the presence of anhydrous NaOAc in glacial AcOH
at reﬂux temperature gave 3-(substituted-phenyl)-5-phenyl-6-
(5-p-tolyl-1,3,4thiadiazol-2-yl)-3,3a,5,6-tetrahydro-2H-pyraz-
olo-3,4-dthiazole derivatives 6a–g in good to excellent yields
(Scheme 1). Their IR, 1H NMR, 13C NMR and MS analyses
conﬁrmed the structures of the synthesized compounds.
In the present work, a series of new compounds were syn-
thesized, Scheme 1 illustrate the path used for the preparation
of target compounds. As starting materials, ethyl p-methyl
benzoate and thiosemicarbazide were used to prepare thiazol-
o-pyrazole derivatives. The structures of the compounds were
elucidated by IR, 1H NMR, 13C NMR and MS analyses. In
the IR spectra of compounds 6a–g disappearance of amide car-
bonyl (C‚O) absorption band at 1683 cm1, which was
present in compounds 5a–g, conﬁrmed the cyclization or
involvement of a, b – unsaturated carbonyl system. The
C‚N, N–H bands of the pyrazole moiety were observed at
about 1580 and 3265 cm1, respectively.In the 1H NMR spectra of compounds 6a–g recorded in
DMSO-d6, the signal due to N–H protons appeared at 8.01–
8.10 ppm as a singlet, the N–CH–Ar proton of thiazole ring
at 5.2 ppm as a singlet, S–CH fused proton at 4.11–4.49 ppm
as a doublet and N-CH fused proton at 4.53–4.91 ppm as a
doublet.
These signals demonstrate that the cyclization step had oc-
curred. All the other aromatic protons of 6a–g were observed
at the expected regions.
In the 13C NMR spectrum of compounds 6a–g recovered in
DMSO-d6. The prominent signals corresponding to the car-
bons of thiazolo-pyrazole ring in all compounds observed
nearly at 67.3, 80.2 and 158.1 ppm, are proof of further evi-
dence of their structures. Mass spectra of all the synthesized
compounds showed M+/M+1 peak, in agreement with their
molecular formulae.
3.2. Antimicrobial activity
The results depicted in Table 1 revealed that most of the tested
compounds displayed variable inhibitory effects on the growth
of the tested Gram positive and Gram negative bacterial
strains, and also against fungal strains.
The antibacterial screening data showed moderate activity
of the test compounds, among the screened 6a, 6b and 6g in
which thiazolo-pyrazole moiety bearing p-chlorophenyl,
p-nitrophenyl and p-bromophenyl nucleus respectively show
38 N. Seelam, S.P. Shrivastavahigh activity against all the microorganisms employed. The
activities of these compounds were almost equal to the stan-
dard. The remaining compounds showed moderate to good
antibacterial activity.
On the other hand the antifungal screening data showed
moderate activity of test compounds, among the screened 6a,
6e and 6f in which thiazolo-pyrazole moiety bearing p-chloro
phenyl, p-methoxy phenyl and 3,4,5-trimethoxy phenyl nucleus
respectively showed high degree of activity against all the mi-
cro organisms employed. The activities of these compounds
were almost equal to the standard. The remaining compounds
also showed moderate to good anti fungal activity.
3.3. Anti tuberculosis activity
The results depicted in Table 2 revealed that most of the tested
compounds displayed variable inhibitory effects on the growth
of the tested M. tuberculosis H37Rv strains.
Generally compounds possessing mesomerically electron
withdrawing and inductively electron donating groups showed
good anti-tubercular activity. Some derivatives (6a, 6b and 6g)
containing electron-withdrawing groups (-Cl, -NO2, -Br) have
shown promising activity against M. tuberculosis H37Rv.
4. Conclusion
In the present paper our aim has been veriﬁed by the synthesis
of 5-(substituted-benzylidene)-2-phenyl-3-(5-p-tolyl-1,3,4thia-
diazol-2-yl)-thiazolidin-4-one (5a–g) and 3-(substituted-phe-
nyl)-5-phenyl-6-(5-p-tolyl-1,3,4thiadiazol-2-yl)-3,3a,5,6-tetra-
hydro-2H-pyrazolo-3,4-dthiazole (6a–g) derivatives, in which
thiadiazole moiety is incorporated with thiazolo-pyrazole moi-
ety in the same molecular framework. The obtained results re-
vealed that most of the tested compounds (6a–g) show
moderate anti bacterial, antifungal and anti tuberculosis activ-
ities comparable with standard commercial drugs and there-
fore become lead molecules for further synthetic and
biological evaluation. Finally it can be concluded that this
class of molecules certainly holds great promise towards the
pursuit to discover novel class of antibacterial, antifungal
and anti tuberculosis agents.Acknowledgments
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